| Identification | Back Directory | [Name]
AZ13705339 | [CAS]
2016806-57-6 | [Synonyms]
AZ13705339
AZ13705339
(AZ 13705339)
2-[[[2-[[3-(Ethylsulfonyl)-4-(4-methyl-1-piperazinyl)phenyl]amino]-5-fluoro-4-pyrimidinyl][5-(hydroxymethyl)-2-methylphenyl]amino]methyl]benzonitrile | [Molecular Formula]
C33H36FN7O3S | [MOL File]
2016806-57-6.mol | [Molecular Weight]
629.75 |
| Chemical Properties | Back Directory | [Boiling point ]
868.7±75.0 °C(Predicted) | [density ]
1.39±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
Soluble in DMSO | [form ]
Solid | [pka]
14.40±0.10(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
AZ13705339 is a highly potent and selective PAK1 inhibitor with IC50s of 0.33 nM and 59 nM for PAK1 and pPAK1, respectively. AZ13705339 has binding affinities to PAK1 and PAK2, with Kds of 0.28 nM and 0.32 nM, respectively. AZ13705339 can be used in the research of cancers[1]. | [in vivo]
AZ13705339 (100 mg/kg, P.O.) has moderate clearance and oral Cmax of 7.7 μM in rats[1]. | [IC 50]
PAK2: 0.32 nM (Kd); PAK1: 0.28 nM (Kd); PAK1: 0.33 nM (IC50); pPAK1: 59 nM (IC50) | [storage]
Store at -20°C | [References]
[1] McCoull W, Hennessy EJ, Blades K, et al. Optimization of Highly Kinase Selective Bis-anilino Pyrimidine PAK1 Inhibitors. ACS Med Chem Lett. 2016;7(12):1118-1123. Published 2016 Sep 14. DOI:10.1021/acsmedchemlett.6b00322
[2] Martin F M de Rooij, et al. A loss-of-adhesion CRISPR-Cas9 screening platform to identify cell adhesion-regulatory proteins and signaling pathways. Nat Commun. 2022 Apr 19;13(1):2136. DOI:10.1038/s41467-022-29835-y
[3] Daniela J Carroll, et al. Siglec-8 Signals Through a Non-Canonical Pathway to Cause Human Eosinophil Death In Vitro. Front Immunol. 2021 Oct 11;12:737988. DOI:10.3389/fimmu.2021.737988 |
|
| Company Name: |
Bide Pharmatech Ltd.
|
| Telephone: |
400-1647117 13681763483 |
| Website: |
https://www.bidepharm.com/ |
|